
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc is showing promising financial trends, with a reported operating expense of $36.4 million, reflecting a modest year-over-year increase of $2.0 million while revenues exceeded consensus expectations in the third quarter of 2025. The company's management has raised its gross margin guidance for 2025 to a range of 76-77%, indicating a focus on improved profitability, alongside a commitment to strategic growth in LDD placements and higher utilization rates. Furthermore, potential upside drivers such as accelerating LDD installed base growth, increased volumes of light adjustable lenses, and enhanced margins reinforce a strong outlook for sustained double-digit revenue growth.
Bears say
RxSight Inc has experienced a decline in key utilization metrics, with monthly utilization for light adjustable lenses dropping to 8.0 per LDD in Q3 2025, down from 8.7 in Q2 2025 and 10.1 in Q3 2024. Revenue for the company fell to $30.3 million, representing a 14% year-over-year decrease, while LDD placements sharply declined by 68% year-over-year and 38% quarter-over-quarter, falling short of investor expectations. Additionally, risks to the company's outlook include limited product adoption, disappointing commercial performance, heightened competition in the intraocular lens market, and the potential need for dilutive financing.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares